TG Therapeutics Investigational Trial Site

Boston, Massachusetts 02215

3 studies enrolling now · 7 studies all time

What they study most

Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma, Multiple Sclerosis, Non Follicular Indolent Non-Hodgkin Lymphoma, Relapsing Multiple Sclerosis, Waldenstrom Macroglobulinemia

Studies at this site

• A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS) — Recruiting now
• A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk — Recruiting now
• Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab — Recruiting now
• Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia — Stopped early
• Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax — Stopped early
• Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma — Completed
• Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) — Completed